Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Healthy
Interventions: morphine sulfate sustained-release capsules, KADIAN; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Bendamustine, Rituximab; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts • Lebanon, New Hampshire

Conditions: Antibiotic-associated Diarrhea
Interventions: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, BB-12, Control Yogurt; Drug · Biological · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy
Interventions: LXR-623; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 19 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Perioperative Chest Pain
Interventions: Lidoderm 5 % Topical Patch, Placebo patch; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Lumbar Puncture, Mercaptopurine, Methotrexate, Positron Emission Tomography, Rituximab, Vincristine Sulfate; Drug · Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 54 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 5 more

Conditions: Post-operative Complications, Surgical Site Infection, Surgical Wound Infection
Interventions: Prevena™ Incision Management System (PIMS), Standard-of-care Dressing; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Cypress, California • Daytona Beach, Florida • Miami, Florida + 2 more

Conditions: Sacroiliitis, Sacroiliac Joint Pain
Interventions: sacroiliac joint injection; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Post Operative Complications
Interventions: Preoperative education, Moderate aerobic exercise, Text messages, Pedometer; Other · Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1 Infected Adults With Chronic HIV-1 Infection
Interventions: Arm A: Poly-ICLC, Arm B: Normal Saline; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Cancer, Von Hippel Lindau
Interventions: ZACTIMA (Vandetanib) (ZD6474); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Ara-C, BL-8040; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 5
States / cities: Jacksonville, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Weight reduction training, PPG training, discrete BG feedback, continuous BG feedback; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 80 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 2 Diabetes Mellitus
Interventions: Omnipod 5 Automated Insulin Delivery System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Atlanta, Georgia • Saint Louis Park, Minnesota

Conditions: End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
Interventions: Ferric Citrate; Drug
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Non Small Cell Lung Carcinoma
Interventions: Pemetrexed, Carboplatin; Drug
Lead sponsor: Instituto Nacional de Cancer, Brazil; Government
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Childhood Cancer
Interventions: Mila Blooms; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 19 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Renal Insufficiency
Interventions: QAW039, QAW39A, QAW39A2107; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Transient Insomnia
Interventions: SM-1, D+Z, D+L, Placebo; Drug
Lead sponsor: Sequential Medicine Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Asthma in Children
Interventions: Clinical decision support + education (CDS+) and population health management (PHM), Control; Behavioral · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Participants
Interventions: AZD5004; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Search by objective public record fields.

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

Mechanisms of Probiotics and Antibiotic-Associated Diarrhea

Study Evaluating LXR-623 in Healthy Subjects

Lidocaine 5% Patch (Lidoderm) for the Prevention of Acute and Chest Pain Following Robotic Valve Surgery

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

Imaging for SIJ Injection Therapy

The Impact of Prehabilitation

Enhancement by Poly-ICLC During HIV-1 Infection

Phase II Study of Vandetanib in Individuals With Kidney Cancer

Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification

Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

A Study of Ferric Citrate to Improve Inflammation and Lipid Levels

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

Mila Blooms Intervention Study

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

SMART Implementation-Effectiveness Trial 2

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection